Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. by Alzoubi, S et al.
Oncotarget44505www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 28
Synergy between histone deacetylase inhibitors and DNA-
damaging agents is mediated by histone deacetylase 2 in 
colorectal cancer
Samer Alzoubi1, Leigh Brody2, Sunniyat Rahman1, Anne-Laure Mahul-Mellier3, 
Nicolas Mercado4, Kazuhiro Ito4, Mona El-Bahrawy5, Andrew Silver6, Alan Boobis1, 
Jimmy D. Bell2, Nabil Hajji1
1Department of Medicine, Division of Experimental Medicine, Centre for Pharmacology & Therapeutics, Toxicology Unit, 
Imperial College London, London, UK
2Department of Life Sciences, Research Centre for Optimal Health, University of Westminster, London, UK
3Laboratory of Molecular and Chemical Biology of Neurodegeneration, Brain Mind Institute, Ecole Polytechnique Fédérale de 
Lausanne,  Lausanne, Switzerland
4Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK
5Department of Histopathology, Imperial College London, London, UK
6Colorectal Cancer Genetics, Centre for Genomics & Child Health,  Blizard Institute, Barts and The London School of Medicine 
and Dentistry, London, UK
Correspondence to: Nabil Hajji, email: n.hajji@imperial.ac.uk
Keywords: colorectal cancer, histone acetylation, drug resistance and in vivo imaging, HDAC2, p53
Received: July 08, 2015    Accepted: May 28, 2016    Published: June 7, 2016
ABSTRACT
Previous studies have associated the overexpression of histone deacetylase 
2 (HDAC2) and the presence of TP53 mutations with the progression to advanced 
stage drug resistant colorectal cancer (CRC). However, the mechanistic link between 
HDAC2 expression and the TP53 mutational status has remained unexplored. Here, 
we investigated the function of HDAC2 in drug resistance by assessing the synergistic 
effects of DNA-targeted chemotherapeutic agents and HDAC inhibitors (HDACis) on two 
TP53-mutated colorectal adenocarcinoma CRC cell lines (SW480 and HT-29) and on the 
TP53-wild type carcinoma cell line (HCT116 p53+/+) and its TP53 deficient sub-line 
(HCT116 p53-/-). We showed that in the untreated SW480 and HT-29 cells the steady-
state level of HDAC2 was low compared to a TP53-wild type carcinoma cell line (HCT116 
p53+/+). Increased expression of HDAC2 correlated with drug resistance, and depletion 
by shRNA sensitised the multi-drug resistance cell line HT-29 to CRC chemotherapeutic 
drugs such as 5-fluorouracil (5-FU) and oxaliplatin (Oxa). Combined treatment with the 
HDACi suberoylanilide hydroxamic acid plus 5-FU or Oxa reduced the level of HDAC2 
expression, modified chromatin structure and induced mitotic cell death in HT-29 cells. 
Non-invasive bioluminescence imaging revealed significant reductions in xenograft 
tumour growth with HDAC2 expression level reduced to <50% in treated animals. 
Elevated levels of histone acetylation on residues H3K9, H4K12 and H4K16 were also 
found to be associated with resistance to VPA/Dox or SAHA/Dox treatment. Our results 
suggest that HDAC2 expression rather than the p53 mutation status influences the 
outcome of combined treatment with a HDACi and DNA-damaging agents in CRC.
INTRODUCTION
Altered expression of histone deacetylases (HDAC) 
is associated with cancer initiation, progression, metastasis 
and drug resistance [1]. This has led to clinical trials 
involving HDACs inhibitors (HDACis) as single or 
combined treatments with DNA damaging agents [2]. 
Moreover, over-expression of HDACs has been implicated 
in the silencing of tumour suppressor genes [3], the 
promotion of genotoxic protection and resistance to DNA 
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damaging agents in many cancer types, possibly through 
the activation of non-histone proteins required for DNA 
stability and higher-order chromatin organisation [4].
Colorectal cancer (CRC) is a common 
gastrointestinal malignancy and the second most common 
cause of cancer-related deaths in the Western world 
[5]. Patients with metastatic CRC (mCRC) have poor 
prognosis [6] and both adjuvant and standard cancer 
therapies remain sub-optimal in a significant number 
of cases due to treatment resistance [7]. Genetic and 
epigenetic alterations are evident in CRC initiation, 
progression and in resistance to conventional drugs [7, 
8]. The tumour suppressor gene TP53 is often inactivated 
by loss of function mutations in CRC [9], although other 
genetic (APC and RAS) or epigenetic alterations (e.g. DNA 
methylation promoter silencing) may compromise TP53 
response to DNA damage [10].
Aberrant expression patterns of HDAC2 are found 
in a number of cancers including CRC [11]. Over-
expression of HDAC2 occurs early at the premalignant 
polyp stage of CRC [12] and correlates with a poor 
prognosis in advanced stage disease [13]. The presence of 
HDAC2 frame shift mutation in cancers from individuals 
with hereditary non-polyposis colorectal cancer syndrome 
caused a loss of HDAC2 protein expression and enzymatic 
activity and rendered tumour cells more resistant to 
trichostatin A, a pan-HDACi [14].
The relationship between the mutational status of 
P53 and HDAC2 overexpression is not well understood 
in CRC drug response and the underlying molecular 
mechanisms of HDACis remain poorly explored [15]. 
HDACis are effective therapeutic anticancer agents 
via multiple mechanisms, which make them very 
attractive agents not only for monotherapy but also for 
combination therapy with other anticancer modalities. 
HDACis can modulate cellular responses to DNA 
damaging agents including ionising and ultraviolet 
radiation, and chemotherapeutic drugs [16]. Many 
HDACi / DNA damaging agent combination strategies 
are both effective and synergistic whereas others are 
ineffective or antagonistic with unclear mechanistic 
reasons for these effects [17]. Hence, understanding 
the mechanisms of HDACi resistance is crucial to 
develop more effective combination strategies for the 
future [18].
The aim of our study was to investigate the role 
of HDAC2 in drug resistance and to assess its impact on 
CRC cell lines with varied TP53 mutation states, (wild-
type, null and mutated) in response to the combined 
treatment with DNA-targeted chemotherapeutics agents 
and HDACis. Our results suggest that HDAC2 expression 
rather than the p53 mutation status influences the outcome 
of combined treatment with a HDAC inhibitor and DNA-
damaging agents in CRC. Furthermore, elevated levels 
of histone acetylation were found to be associated with 
drug resistance in our cellular models. This is particularly 
significant as we show that HDAC2 expression is 
increased in moderately differentiated human metastatic 
colorectal carcinomas in the liver compared with 
normal tissues. Taken together, our results demonstrate 
the potential of using HDAC2 expression levels as a 
biomarker in understanding the effectiveness of combined 
treatment.
RESULTS
The response of wild type, null, and mutated 
TP53 CRC cell lines to DNA damaging agents
Mutations in TP53 tumour suppressor gene 
are well-known events, which take place in the most 
aggressive cancers. However, the significance of 
mutated TP53 in drug resistance is controversial in many 
cancers. In this study, we investigated the role of p53 
in the induction of CRC cell death by DNA damaging 
agents in the presence or absence of wild-type p53. 
The wild type (WT) TP53 cell line HCT116 (HCT116 
p53+/+) was treated with increasing concentrations 
(0.1-3 μM) of the DNA damaging agent doxorubicin 
(Dox), a topoisomerase II inhibitor. Incubation of 
HCT116 p53+/+ cells with 0.5μM Dox was sufficient 
to phosphorylate multiple p53 serine residues 
(Ser15, Ser37, and Ser20). These post-translational 
modifications (PTM) led to p53 accumulation in cells 
(Figure 1A). Dox was able to induce apoptosis in 
concentration-dependent manner as shown by PARP 
cleavage (PARPc) (Figure 1A). Acetylation of p53 
at residue K382 as contributor of its activation was 
observed after exposure to 1-3μM Dox followed by 
substantial increase of PARPc (Figure 1A). Therefore, 
we sought to determine the role of p53 in controlling 
the sensitivity to Dox. The TP53 WT (HCT116 p53+/+) 
and null isogenic TP53 (HCT116 p53-/-) cell lines 
were treated with 1μM Dox and assessed for PARPc 
by immunoblotting (Figure 1B). HCT116 p53-/- cells 
were less sensitive to 1μM Dox treatment and showed 
less cell death in comparison with HCT116 p53+/+ 
suggesting that in absence of p53, the cells were less 
sensitive to Dox treatment compared to HCT116 p53+/+ 
cells (Figure 1A and 1B). To confirm the importance of 
the TP53 gene in regulating DNA damage responses, 
SW480 and HT29 cells with TP53 mutations were used. 
SW480 has two mutations in TP53: one is similar to that 
in HT-29 (mutation in TP53 DNA-binding site, codon 
273; and the second is located in the P53 oligomerisation 
domain, codon 309). The Dox sensitivity of the two 
mutated cell lines were compared to HCT116 p53+/+ 
and HCT116 p53-/- cell lines. HT-29 cells were treated 
with 0.5 μM, 1μM and 2 μM Dox which all failed to 
induce PARPc (Figure 1C). Surprisingly, PARPc 
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was observed in SW480 treated with much lower 0.5 
μM and 1μM concentrations of Dox (Figure 1C and 
1D). To determine if the difference in sensitivity was 
Dox specific, additional drugs were tested including 
cisplatin and camptothecin, and also 5-fluorouracil (5-
FU) and Oxaliplatin (Oxa) both of which are first-line 
chemotherapeutic agents used to treat patients with 
Dukes’ B and C CRC. Low and high concentrations were 
selected for each drug treatment. As HT-29 exhibited 
more resistance to Dox compared to the other cell lines, 
only the high concentrations of selected drugs were 
used. HT-29 cells exhibited extreme resistance to all 
drugs tested compared to the other cell lines, HCT116 
p53+/+ and HCT116 p53-/-, as demonstrated by PARPc 
(hallmark of apoptosis) (Figure 1E and 1F).
HDAC inhibitors in combination with DNA 
damaging agents induce distinct levels of 
sensitivity to the induction of cell death in CRC 
cells
To characterise whether HDACis work 
synergistically in combination with DNA damaging 
agents; three HDAC inhibitors were used, 
suberoylanilide hydroxamic acid (SAHA or vorinostat), 
as an example of a pan HDACi active against class I 
and class II HDACs; the short-chain fatty acid sodium 
butyrate (NaB) and valproic acid (VPA), a class I 
and class IIa HDAC inhibitor. To determine whether 
any synergistic effects, low concentrations of DNA 
damaging agents were selected and combined with the 
Figure 1: Characterization of WT, null, and mutated P53 CRC cell lines response to DNA damaging agents. A. HCT116 
P53+/+ cells were treated with dose-increase of Dox for 24hr and checked for PARP cleavage, also activation and stabilization of P53 
were analyzed by western blotting. B. Comparison of PARP cleavage upon Dox 1μM between HCT116 P53+/+ and HCT116 P53-/-. C. 
Assessment of PARP cleavage in SW480 and HT-29cells lines upon a dose-increase of Dox. D. HCT116 P53+/+, HCT116 P53-/-, and HT-
29 cells were treated with 1μM Dox and proteins cell lysate were separated using SDS-PAGE and detected by WB analysis. Quantification 
of PARP cleavage detected by western blotting was performed by ImageJ software and based on the ratios of normalized cleaved PARP 
by βactin and normalized uncleaved PARP. (Fold changes are the average of three independent of three independent experiments (n=3)). 
E. HCT116 P53+/+ cells, HCT116 P53-/- and HT-29 cells were treated with chemotherapeutic drugs for 24hr. Cells were lysed and the 
proteins separated using SDS-PAGE and detected by WB analysis. The cleavage of PARP was assessed using the appropriate antibodies. 
F. HT-29 cell death investigated by propidium iodide (PI) staining and flow cytometry analysis (mean ± S.E.M. of three independent 
experiments (n=3)), the cell death following treatments with (5-FU and Oxa) were not significant in comparison with the control (P=0.55), 
and this supports the results western blot for these treatments (no PARPc). In all the western blotting experiments βactin was used as a 
loading control.
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HDACis. HCT116 p53+/+ and HCT116 p53-/- were 
treated with a single treatment of Dox (0.5μM) and 
Camptothecin-11 (CPT-11) (5μM) or combined with 
VPA (1 mM), SAHA (0.5μM), and NaB (1 mM) for 24 
h and then analysed for cell death by flow cytometry. 
Significant cell death was observed following SAHA 
and NaB as a single treatment in HCT116 p53+/+ but 
only a slight increase in HCT116 p53-/- (Figure 2A). 
The combined treatments in HCT116 p53+/+ induced 
a synergistic effect on cell death in comparison with 
the single treatment, whereas HCT116 p53-/- showed 
a synergistic effect only with Dox/SAHA (Figure 2A). 
However, in HCT116 p53-/- cells an antagonistic effect 
on cell death was observed with the Dox/VPA and CPT/
NaB combinations. Antagonistic effects on HT-29 cell 
death were observed with Dox at 0.5 μM and 2 μM 
combined with SAHA and CPT/SAHA (Figure 2B). 
Interestingly, only the combined treatments, SAHA/5-
FU and SAHA/Oxa showed synergistic effects on HT-29 
cell death (Figure 2B).
HDAC2 expression after drug treatment with 
DNA damaging agents singly or combined with 
HDACis
HDAC2 overexpression and p53 mutations are 
significantly associated with advanced stages and 
poor prognosis in CRC patients [13]. However, the 
relationship between HDAC2 and p53 status is not 
completely understood nor the role and regulation 
of HDAC2 expression level upon drug treatments. 
Therefore, we investigated the relationship between 
HDAC2 expression level and the effect of DNA 
damaging agents as single treatments or combined with 
HDACis in CRC cells lines. Cells were exposed for 24 
h to increasing concentrations of Dox, Oxa and 5-FU 
followed by the assessment of HDAC2 and PARPc 
protein level by immunoblotting. We observed a dose-
dependent decrease in HDAC2 protein expression 
(P<0.001), which was inversely proportional to PARPc 
increase in HCT116 P53+/+ cells (Figure 3A and 3B). 
In contrast, upon exposure to different concentrations of 
the drugs, HT-29 cells exhibited extreme resistance to 
PARPc induction and a significant increase in HDAC2 
protein expression (P<0.001) (Figure 3A and 3B).
The effect of combined treatment on HDAC2 
protein levels was investigated in the four CRC cell 
lines with different TP53 mutational status: HCT116 
p53+/+, HCT116 p53 -/-, SW480, and HT-29. All cell 
lines were treated for 6 and 24 hours with the different 
combinations of the drugs. At 6 hours, the p53+/+ cell 
line exhibited sensitivity to the VPA/Dox and SAHA/
Dox combinations, but not to the single treatment as 
measured by PARPc (Figure 3C). In HCT116 p53+/+ 
cell death correlated with a significant decrease in 
HDAC2 expression (P<0.001) (Figure 3C and 3D). 
However, null p53, SW480 and HT-29 showed a marked 
increase of HDAC2 following single or combined 
treatments, which correlated with resistance to the 
treatment (Figure 3C and 3D).
HDAC2 mRNA levels were also affected by the 
drugs treatments. In HCT 116 p53+/+ cells, HDAC2 
mRNA was reduced significantly (P < 0.001) following 
Dox or VPA as single treatment or combined. In contrast 
HT-29 cells exhibited a significantly increased HDAC2 
mRNA expression (P < 0.001) upon the combined 
treatment Dox/VPA (Figure 3E).
At the 24 hour time point, responses to the applied 
treatments were classified in terms of sensitivity along the 
following scale: HCT116 p53+/+ was the most sensitive, 
then SW480, HCT116 p53-/-, and finally HT-29 (Figure 
4A). HDAC2 expression levels increased significantly 
(P<0.001) with treatment, which correlated with drug 
resistance (Figure 4A-4B). As HDAC1 and HDAC2 could 
play compensatory functions in regulating apoptosis, we 
tested HDAC1 expression level. Our data showed no clear 
correlation of HDAC1 with cell death in any cell lines 
(Figure 4A).
To substantiate the importance of HDAC2 in CRC 
drug resistance, exogenous WT P53 was transfected 
into HT-29 cells and into HT-29-ShRNA-HDAC2 
cells followed by Oxa treatment (Figure 4C). Notably, 
the introduction of WT P53 did not induce cell death 
following treatment as examined by the apoptotic end-
point of PARP cleavage. Combined treatments were also 
investigated through the use of Oxa/SAHA in both HT29 
and HT-29-ShRNA-HDAC2 cell lines and UV was used as 
a positive control. Cell death analysis via flow cytometry 
showed that exogenous WT P53 alone did not sensitise 
HT-29 to Oxa treatment, rather WT p53 in combination 
with shRNA-mediated HDAC2 induced treatment 
sensitivity (Figure 4C and 4D).
Functional p53 is crucial for cancer chemosensitivity 
and associated mutations lead to drug resistance and 
shorter patient survival in different cancers. Thus, we 
investigated the significance of p53 mutations in response 
to the DNA damaging agent Dox. Several stable cell lines 
with crucial p53 mutations were generated using both null 
P53 HCT 116 and HT-29 cells. All generated p53 mutants’ 
cells were treated with 0.5μM Dox and cell death was 
measured by PI staining and flow cytometry analysis. 
Our data showed that TP53 WT P53 does not sensitise 
HT-29 to Dox. Surprisingly, mutations (S15A, K120R, 
K373R and K381R; Figure 5A-5C) were able to sensitise 
significantly HT-29 cells to Dox (P<0.001).
However, HDAC2 depletion was sufficient to 
sensitize HCT116 p53-/- cells to Dox and induce cell 
death (P<0.001) (Figure 6A). Furthermore, transient 
HDAC2 over-expression in both drug sensitive cell lines 
HCT 116 p53+/+ (Figure 6B) and mutated TP53 SW480 
cells (Figure 6C) increased the resistance against single 
and combined treatments significantly (P<0.001).
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Figure 2: Combined treatment with distinct HDAC inhibitors and DNA damaging agents induces different levels 
of sensitivity in CRC cells. A. HCT116 p53+/+, HCT116 p53-/- cells were treated with a single treatment of Dox (0.5μM) and 
Camptothecin-11 (CPT-11) (5μM) or combined treatment with VPA (1 mM), SAHA (0.5μM), and sodium butyrate (NaB) (1 mM) for 
24 h and then cells were prepared for the cell death analysis by flow cytometry using Propidium iodide (PI) staining. We calculated the 
combination index (CI) according to the Chou-Talalay method using Calculsyn software (Biosoft, Cambridge, UK). Chou-Talalay method 
for drug combination was based on the median-effect to defined synergy and antagonism [38]. This method offered synergistic (CI < 1), and 
antagonistic effect (CI > 1) in drug combinations. Error bars represent ± S.E.M of three independent experiments (n=3). B. HT-29 cell death 
analysis by flow cytometry after 24 hours treatment with (Dox, CPT, 5FU), SAHA or their combination. Cells were harvested and stained 
with Propidium iodide (PI) to determine cell death using FACS analysis. * denotes a synergistic effect and X denotes an antagonistic effect. 
Error bars represent ± S.E.M of three independent experiments (n=3).
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HDAC2 controls chromatin plasticity and its 
depletion enhances mitotic cell death in drug 
resistant HT-29 cells upon 5-FU and Oxa 
treatment
We have shown that HT-29 cells were resistant 
to Dox combined with HDACis. Moreover, WT P53 
overexpression was not sufficient to sensitise HT-29 
to Oxa, in contrast to exposure UV exposure (positive 
control), which induced significant PARPc and cell 
death in both cells (Figure 4C). HT-29 cells showed a 
significant response to cell death when 5-FU or Oxa 
was combined with SAHA. Surprisingly, no PARPc was 
induced (Figure 7A), although there was significant cell 
death detected by flow cytometry analysis (Figure 2B 
and Figure 4D). This indicated that cell death induced 
by both combinations in HT-29 cells did not involve 
PARPc excluding the apoptotic cell death. Interestingly, 
we observed that the type of cell death induced in these 
cells was largely mitotic cell death (MCD) as detected 
Figure 3: Early effects of Dox combined to SAHA or VPA on CRC cell lines. A and B. HCT116 and HT-29 cells were treated 
for 24 hr treatment with dose-increase of Dox, Oxa or 5-FU. Cells were lysed and the proteins separated using SDS-PAGE and detected 
by WB analysis. The cleavage of PARP (PARPc) and the protein level of HDAC2 were assessed and quantified using the appropriate 
antibodies. Actin was used as a loading control. C. The four cell lines (HCT116 p53+/+, HCT116 p53-/-, SW480, and HT-29) were treated 
for 6 hours with Dox, VPA or SAHA only or as a combined treatment. Cells were lysed and the proteins separated using SDS-PAGE and 
detected by WB analysis. The PARPc and the protein level of HDAC2 were assessed using the appropriate antibodies. Actin was used as 
a loading control. D. Four cell lines were treated with Dox either singly or combined with SAHA or VPA for 6 hours and cells were lysed 
and the proteins separated using SDS-PAGE and detected by WB analysis. HDAC2 protein levels were assessed using the appropriate 
antibodies and quantified using ImageJ software. E. Total RNA was extracted from HCT116 p53+/+ and HT-29 cells and HDAC2 mRNA 
expression level was measured by quantitative RT-PCR using the primer: forward primer (5’-3’) GT GAG ATT CCC AAT GAG TTG C. 
reverse primer (5’-3’) GGT AAC ATG CGC AAA TTT TCA A. Error bars represent ± S.E.M.; n=3 independent experiments. Test, t-test, * 
for p<.005, ** for p<.001, and *** for p<.0001.
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by phosphorylated histone 3 (a mitotic cell marker) 
(Figure 7A-7C), Interestingly no cell cycle arrest was 
observed (data not shown).
To investigate the role of HDAC2 in MCD, shRNA-
mediated knockdown of HDAC2 was achieved in HT-29 
cells. These were then treated with 5-FU, Oxa and SAHA 
and compared to their parental cells following measurement 
of both PARPc and MCD (Figure 7D and 7E). HDAC2 
knockdown was sufficient to sensitise HT-29 cells to 
5-FU or Oxa treatment and only the combined treatments 
were able to reduce HDAC2 expression as detected by 
immunohistochemistry similar to HDAC2 knockdown 
effect (Figure 7F). We noticed that the combined treatment 
Oxa/SAHA induced chromatin relaxation as assessed by 
micrococcal nuclease (MNase) assay (Figure 7G). Oxa 
combined with shRNA-HDAC2 disturbed the higher 
order chromatin structure in a similar manner to the Oxa 
combination with SAHA (Figure 7F, Zeta Stack).
Figure 4: Characterisation of HDAC2 expression levels in distinct CRC cell lines and its relationship with P53 and 
resistance to HDACis combined with DNA damaging agent doxorubicin. A. HCT116 p53+/+, null p53, SW480 and HT-29 
cells were treated with Dox either singly or combined with SAHA or VPA for 24 hours. Cells were lysed and the proteins separated using 
SDS-PAGE and detected by WB analysis. The cleavage of PARP, a hallmark of apoptosis and the protein level of HDAC1 and HDAC2 
were assessed using the appropriate antibodies. Actin was used as a loading control. B. Four cell lines were treated with Dox either singly or 
combined with SAHA or VPA for 24 hours and cells were lysed and the proteins separated using SDS-PAGE and detected by WB analysis. 
HDAC2 protein levels were assessed using the appropriate antibodies and quantified using ImageJ software. C and D. P53 expression 
vectors were transiently transfected into HT-29 cells and HT29-ShRNA-HDAC2 cells, The cells were treated with Oxa (10μM) for 24 
hours. Cells were lysed and the proteins separated using SDS-PAGE and detected by WB analysis. The PARPc and the protein level of 
p53 were assessed using the appropriate antibodies. Actin was used as a loading control. D) P53 transfected cells were also analyzed for 
cell death using PI staining and FACS analysis. Cells treated with SAHA+ Oxa or illuminated by UV-C (50 mJ/m2) were used as positive 
controls. Error bars represent ± S.E.M. of three independent experiments (n=3) and statistical significance is depicted by (*) for p<0.05 
calculated by a two-tailed Student’s T test compared to the control group.
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Liposomal-encapsulated Dox/SAHA treatment 
down-regulates HDAC2 expression in CRC 
xenografts
To substantiate the relationship between HDAC2 
expression level and the induction of cell death in vivo 
by combined treatment, non-invasive spatiotemporal 
visualisation was used based on a bioluminescent 
molecular imaging of a murine xenograft model. 
Luciferase stable cell lines HCT116 p53 +/+ and 
HCT116 p53-/- were generated and transplanted 
into nude mice. Since the combined treatment Dox/
SAHA produced significant cell death in both cell 
lines in vitro, the in vivo validation of this effect was 
explored. For this, liposomal-encapsulated Dox/SAHA 
was prepared and used to treat human CRC xenografts 
in mice [19]. The size of the tumour was measured 
before treatment and every three days during the study 
using callipers. Mice with xenografts of HCT116 p53 
+/+ and HCT p53 -/- exhibited a significantly lower 
tumour volume and luciferase activity in response to the 
combined treatment (p<0.005) (Figure 8A and 8B). The 
immunohistochemistry analyzes for HDAC2 expression 
levels in the tumour isolated from HCT116 p53+/+ 
xenograft mice showed a more significant decrease 
after Dox/SAHA combination treatment (P<0.005) 
(Figure 8C).
Survivin, an inhibitor of apoptosis is 
overexpressed in the majority of cancer types and is 
associated with chemotherapeutic resistance, reduced 
apoptosis and increased tumour recurrence. Survivin 
protein levels were measured by immunohistochemistry 
(IHC) analyzes of tumours isolated from HCT116 
p53+/+ xenograft mice. The results showed a significant 
Figure 5: TP53 mutations (S15A, K120R, K373R and K381R) sensitise HT-29 to Dox treatment. A. Overexpression of 
mutations (S15A, K120R, K305R K320R, K372R K373R, and K381Rand K382R) in null P53 HCT-116 cells. All p53 mutants’ cells were 
treated with 0.5μM Dox and cleavage of PARP was detected by WB. B. Cell death analysis by flow cytometry. Stable clone HCT116 p53-/- 
cells were treated with 0.5μM Dox for 24 hours and cell death was assayed by incubating live cells with propidium iodide. C. Stable HT-29 
cell line was generated from selected mutants (S15A, K120R, K373R and K381R). Cell death analysis was assessed by FACS after 0.5 μM 
Dox treatment for 24 hours and propidium iodide staining. Error bars represent ± S.E.M.; n=3 independent experiments. Test, t-test, * for 
p<.005, ** for p<.001.
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Figure 6: Modulation of HDAC2 expression level by depletion or overexpression directly influences the effect of Dox 
as single or combined to HDACis in CRC cells. A. Stable ShRNA-HDAC2 HCT116 p53-/- cells were generated by using lentiviral 
vector and HDAC2 downregulation was confirmed by WB. Actin was used a loading control. Cells were exposed for 24hr to Dox as single 
treatment or combined with VPA. Protein cell lysates were separated by SDS-PAGE and detected by WB analysis. The PARPc protein level 
was assessed using the appropriate antibodies. Actin was used as a loading control. Cells were also harvested and stained by PI to determine 
cell death using FACS analysis. Error bars represent ± S.E.M. of three independent experiments (n=3) and statistical significance is depicted 
by * for p<0.05 calculated by a two-tailed Student’s T test compared to the control group. B and C. HCT16 p53+/+ and SW480 cell lines 
were transfected with HDAC2 vector. After 24 hours post-transfection, cells were lysed and the proteins separated using SDS-PAGE. The 
overexpression of HDAC2 level was detected by WB and quantified using ImageJ densitometry software. HCT16 p53+/+ and SW480 cells 
transiently transfected with HDAC2 vector were treated with Dox only or combined with VPA or SAHA. After 24 hours, cells were lysed 
and the proteins separated using SDS-PAGE. The PARPc was analyzed by WB and cell death was quantified by FACS after PI staining. 
Error bars represent ± S.E.M. of three independent experiments (n=3) and statistical significance is depicted by * for p<0.05 calculated by 
a two-tailed Student’s T test compared to the control group.
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decrease in survivin levels after Dox/SAHA combination 
treatment (P<0.005) (Figure 8C). IHC analyzes of 
human CRC metastases in liver (n=10) and matched 
normal human liver tissues (n=10) found higher levels 
of HDAC2 and survivin in the former compared to the 
latter (Figure 8D). We also assessed the expression of 
survivin in HT-29 compared with the other cell lines 
and showed that following SAHA/Dox or VPA/Dox 
treatment, there was a significant increase of survivin 
expression and that this was proportional to a decrease 
in HDAC2 expression (Figure 9).
Figure 7: HDAC2 controls the chromatin plasticity and its depletion enhances mitotic cell death in drug resistant 
HT-29 cells upon 5-FU and Oxa treatments. A. PARPc measurement in HT-29 treated by 5-FU and Oxa combined with SAHA. 
After 24 hours, cells were lysed and the proteins separated using SDS-PAGE. B and C. HT-29 cell lines were treated by 5-FU or Oxa alone 
or combined with SAHA. After 24 hours, Cells were fixed 4% paraformaldehyde, subsequently DNA was stained with DAPI (0.1 μg/
ml; Sigma-Aldrich) and the number of apoptotic cells was measured quantitatively by assessing the percentage of cells with fragmented 
or condensed nuclei. Mitotic cell death (MCD) was quantified by using phosphorylated histone 3 (ser10) as a mitotic cell marker. C) 
Representative image of mitotic cell death (MCD) in HT-29 upon SAHA + Oxa combined treatment. D. HT-29 or shRNA-HDAC2 HT-29 
cells lines were treated with 5-FU or Oxa only or in combination with SAHA. After 24 hours, cells were lysed and the proteins separated 
using SDS-PAGE. The PARPc and the protein level of HDAC2 were analyzed by WB. Actin was used as a loading control. E. HT-29 
cell lines or shRNA-HDAC2 HT-29 cells lines were treated by 5-FU, Oxa or SAHA. After 24 hours, mitotic cell death (MCD) was 
quantified by using phosphorylated histone 3 (ser10) as a mitotic cell marker. F. HT-29 cell lines were treated by Oxa alone or combined 
with SAHA and shRNA-HDAC2 HT-29 cells were treated with Oxa. After 24 hours, cells were fixed and HDAC2 protein was detected 
after immunofluorescence staining. Nucleus was counterstained using DAPI staining. + z-Stack shows nuclear deformation. G. MNase 
accessibility assay was used to study relaxed chromatin which has higher accessibility to micrococal nuclease enzyme (MNase). Cells 
HT-29 cells were treated with Oxa or SAHA alone or combined for 24hr and chromatin was extracted and incubated with 0.06U of MNase 
and fragmented DNA was separated by gel agarose, the arrow represent the undigested DNA. For all the experiments error bars represent ± 
S.E.M. of three independent experiments (n=3) and statistical significance is depicted by * for p<0.05 calculated by a two-tailed Student’s 
T test compared to the control group. Actin was used as a loading control.
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Doxorubicin combined with SAHA or VPA 
triggers a decrease in histone acetylation
To determine if there was a correlation between 
histone acetylation and the sensitivity of CRC cell 
lines to combined treatment. The levels of histone 
acetylation in HCT116 p53+/+, HCT116 p53-/- (poorly 
differentiated) and SW480 (poorly differentiated and 
invasive) were compared to the well-differentiated CRC 
cell line HT-29. All cell lines were exposed to Dox, 
VPA, and SAHA as a single or combined treatment 
and the changes in histone acetylation established. Dox 
(1μM) induced significant cell death in HCT116 p53+/+, 
SW480, HCT116 p53-/- and with no effect on HT-29. 
Therefore, the effect of combined treatment on histone 
acetylation was compared using this concentration. 
Interestingly, Dox combined with SAHA or VPA 
triggered a decrease in histone acetylation in the poorly 
differentiated and sensitive CRC cells, but not in the 
resistant and well-differentiated HT-29 cells. In HT-
29 cells, the H3K9ac, H4K12ac and H4K16ac levels 
remained high after the combined treatments compared 
to the other cell lines (Figure 10).
Figure 8: In vivo imaging and validation of the effect of combined treatment by liposome-encapsulated SAHA/Dox 
in xenograft mice. A-B. HCT116 p53+/+ or HCT116 p53-/- expressing sable luciferase-reporter were transplanted intraperitoneally in 
male BALB/c nude/nude mice. Liposomal SAHA/Dox-was used to treat HCT116 p53+/+ (n=4) or HCT116 p53-/- (n=4) xenograft mice 
groups compared to each control groups (n=4). Tumor size manually measured with calipers every three days and bioluminescence imaging 
measurement every week. Error bars indicate ± SEM (n = 4 replicates). *P <0.005; two-tailed t-test, Imaging was performed by using 
LICOR. Quantitation of luciferase intensity (error bars indicate ± SEM; n = 4 replicates). P < 0.005, two-tailed t-test). C. Protein levels 
of HDAC2 and survivin in control and treated tumour xenografts of HCT116 P53+/+ were analyzed by immunohistochemistry (HDAC2 
expression was found in the nuclei of all control cells and in <50% of treated tumour cells). D. Protein levels of HDAC2, survivin, and P53 
in normal human liver tissue and liver metastasis of CRC. All antigens were strongly expressed in CRC in contrast to absent or significantly 
less abundant in normal liver cells. Imaging was performed by using LICOR. (Right) Quantitation of luciferase intensity (error bars indicate 
± SEM; P < 0.005, two-tailed t test, n = 4 replicates).
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Figure 10: Dox combined with SAHA or VPA triggers induces histone hypo-acetylation. A. Histones were extracted by acid 
from the four cell lines (HCT 116 p53+/+, HCT116 p53-/- SW480 and HT-29) after exposure to Dox, VPA, SAHA or different combinations 
of these drugs for 24hours, also the cells were treated with 1μM. Extracted histones were separated using SDS-PAGE and detected by WB 
analysis. Histone acetylation levels at residues H3K9 and H4 (K12 and K16) were assessed using the appropriate antibodies. Total H3 
and H4 protein levels were used as loading control. B. Quantifications of acetylated H3K9, H4K16, H4K12 residues in HCT116 P53+/+, 
SW480, HCT116 P53+/+, and HT-29 was measured by ImageJ software. Cells were treated only with Dox, VPA or SAHA or by different 
combinations of these drugs. The changes are presented as fold change in comparison to the control. Error bars represent ± S.E.M.; n=3 
independent experiments. One-way ANOVA, Dunnett post-test, P =0.0001.
Figure 9: Dox/SAHA combination decreases drastically survivin protein level in HCT 116 p53+/+, HCT116 p53-/- and 
SW480 but not HT-29 cell lines. Four cell lines (HCT 116 p53+/+, HCT116 p53-/- SW480 and HT-29) were treated with Dox, VPA, 
SAHA or different combinations of these drugs for 24hours. Cells were lysed and the proteins separated using SDS-PAGE and detected by 
WB analysis. The protein level of Survivin and p53 were assessed using the appropriate antibodies. Actin was used as a loading control.
DISCUSSION
We have shown that reduction in HDAC2 
expression level plays an essential role in CRC response to 
DNA damaging agents alone or combined with HDACis. 
We demonstrated that mutated TP53 HT-29 cells exhibit 
extreme resistance to drugs, whilst mutated TP53 SW480 
showed comparable sensitivity to drugs as WT p53 cells. 
The combined treatment effect was compared with the 
single treatment alone. All combined treatments tested 
were found to exert a synergistic effect on cell death in 
CRC WT p53 cells, whereas cell death induced in null p53 
cells shifted from synergistic with Dox/SAHA and CPT/
SAHA combinations to antagonistic with Dox/VPA and 
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CPT/NaB combinations. These results point to a limited 
role for TP53 in response to Dox/SAHA combination 
therapy since Dox/SAHA exerted a synergistic effect on 
cell death in wild type and null p53 cells. In addition, 
reconstitution of p53 protein in HCT 116 p53-/- and HT-
29 cells was not able to increase their sensitivity to drug 
treatment and, surprisingly, mutated p53 (S15A, K120R, 
K373R and K381R) sensitised null p53 or HT-29 to Dox.
Reintroducing WTp53 into drug-resistant CRC 
mutated P53 HT-29 cells does not sensitise cells to 
conventional CRC treatments Oxa and 5-FU. WTp53 
overexpression is considered as a pro-apoptotic protein 
and several studies showed this is possible when the 
WTp53 is introduced in functional p53 cancer cells. 
However, it is not always the case when cancer cells 
have non functional P53 [20–22], which suggests 
that the function of mutant P53 could not be rescued 
when exogenous WTp53 is introduced. Another study 
demonstrated that the p53 protein expressed in H1299 
with no endogenous p53 cells does not seem to function 
as normal WTp53 despite the fact that DNA damaging 
agents allow the protein to stabilise and accumulate in the 
cell [20]. Hence, H1299 cell may have switched to other 
mechanisms for dealing with DNA damage, since there 
is no p53 protein expression in H1299 [20]. Therefore, 
the reconstitution of WTp53 alone is not sufficient to 
substantially alter the sensitivity of cancer cells to a 
given chemotherapeutic agent [20–22]. Thus, for the drug 
regimens used here, TP53 mutational status may be of less 
significance in CRC drug resistance.
Previous studies have reported variation in cancer 
cell death among cells with differing p53 mutational status 
[22]. For example cells with WT p53, are able to activate 
AMP-activated protein kinase (AMPK) and protect 
cancer cells from autophagy to counteract the cytotoxicity 
caused by the DNA-damaging agent. Conversely, non-
functional p53 (mutated) is unable to activate AMPK and 
cause autophagic cell death [23]. Additionally, PARPc is 
involved in the molecular mechanisms of various forms of 
cell death (including apoptosis, necrosis and autophagy) 
[24]. The appearance of PARPc in the Dox treated mutated 
cells could cause a similar cell death pathway.
In WT p53, null p53 and mutated p53 (SW480) cell 
lines treated with SAHA or VPA combined with Dox, a 
significant decrease in the expression level of HDAC2 
is observed when apoptosis is induced, as shown by 
PARPc or propidium iodide uptake. On the contrary, 
treatment with the same combinations, MT p53 (HT-
29) cell line showed an increase in HDAC2 protein 
expression with resistance to cell death. Furthermore, 
HDAC2 overexpression in MT p53 SW480 cells confers 
resistance to the combined treatment. This suggests that 
TP53 mutations in CRC do not confer as much protection 
against the effect of SAHA or VPA combined with Dox 
as one would expect, rather it is the HDAC2 protein 
levels that appear to confer a protective phenotype. Like 
HDAC2 expression, HDAC1 also seems to be upregulated 
in CRC [25]. Whilst HDAC2 expression level increased 
significantly with resistance to treatment, HDAC1 
expression had no clear correlation across all cell lines. 
We also established an in vivo model to verify HDAC2 
expression levels and to evaluate the response to combined 
treatments. Liposomal-encapsulated Dox/SAHA was used 
to treat human CRC xenografts mice as an innovative 
delivery strategy for toxicity reduction. We found that 
the combined treatment induced a proportional and 
significant decrease in HDAC2 expression level, which 
were associated with tumour shrinkage as measured by 
tumour size and luciferase activity. Similarly, combined 
treatment led to a reduction in tumours from both WT p53 
and a null p53 cells, again suggesting that p53 is a poor 
prognostic marker compared to HDAC2 expression.
Deletion of HDAC2 without drug treatment is not 
sufficient to induce cell death [26]. Here we show that, 
although HDAC2 depletion is not sufficient for cell death 
it leads to perturbations in the higher order chromatin 
structure similar to the effects of HDACis and increased 
HT-29 sensitivity to 5-FU and Oxa leading to MCD. 
Whilst the mechanism of HDAC2 inactivation and drug-
induced cell death remains largely unknown, recent 
microarray analysis of HDAC2 inactivation in human 
hepatocellular carcinoma (HCC) identified a large number 
of mitotic gene elements including the up-regulation 
of cell cycle inhibitors and down-regulation of cyclin 
target genes [27]. The increase of HDAC2 expression 
has been found in CRC patients at mRNA and protein 
level indicating that HDAC2 overexpression is due to 
transcriptional activation [11]. This overexpression of 
HDAC2 appears to be implicated in cancer through its 
aberrant recruitment to promoter of tumour suppressor 
genes leading to gene silencing [28]. HDAC2 transcription 
is regulated by β-catenin-TCF signalling pathway that is 
deregulated in CRC. Histone acetyltransferase p300/
CREB-binding protein (CBP) is a crucial coactivator for 
β-catenin-TCF-mediated survivin transcription [28] and 
the complex regulation of survivin transcription involves 
enhancement by β-catenin and repression by p53 [29]. As 
the relationship between survivin and HDAC2 has not 
been explored in the combinatorial treatment of CRC we 
investigated this in mice xenograft tumours. Treatment 
with SAHA/Dox gave a significant reduction in protein 
expression for both HDAC2 and survivin. Also, we found 
increased levels of HDAC2 and survivin expression in 
human CRC metastatic liver tissues.
Compact chromatin is crucial for the protection 
against agents causing DNA breaks and oxidative DNA 
damage and this protection is reduced following chromatin 
relaxation [30]. Using a chromatin relaxation assay, we 
demonstrated that mutated p53 HT-29 cell line showed 
relaxed chromatin only after combined Oxa/SAHA 
treatment. This supports our previous finding, where in 
the absence of functional p53, SIRT1 (HDAC class III) 
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expression level is a critical parameter in trichostatin A 
or VPA-mediated sensitisation of several multidrug-
resistant cancer cells to the topoisomerase II inhibitor 
etoposide [2]. HDACis allow for increased histone 
acetylation and the subsequent chromatin relaxation that 
occurs may render DNA more susceptible to a number of 
DNA-damaging agents [31] and increase the binding of 
transcription factors that regulate genes involved in cell 
death. Interestingly, it has been suggested that p53 has the 
biochemical potential for promoting chromatin relaxation, 
since it can recruit the histone acetyltransferase (HAT) 
p300 to chromatin. This could facilitate histone acetylation 
[32] and hence induce chromatin accessibility to enable 
the efficient detection of lesions [33–35].
Recent studies have shown that the acetylation of 
H3 or H4 is decreased in poorly differentiated cancer 
cells while the global expression in moderate to well 
differentiated cancer cells is increased [36]. However, it is 
unclear whether such differences in steady state acetylation 
levels could be indicative of resistance to drugs used 
singly or combined with HDACis. With this perspective 
in mind, we demonstrated that Dox combined with SAHA 
or VPA triggers a decrease in histone acetylation in 
poorly differentiated and sensitive CRC cells, including 
SW480 cells, but not in well-differentiated and resistant 
HT-29 cells. Therefore, in HT-29 the H3K9ac, H4K12ac 
and H4K16ac levels remain elevated after the combined 
treatments compared to the other cells. Our results are in 
agreement with the elevated level of lysine 9-acetylated 
histone H3 that occurs at the multi-resistance protein 
1 (MDR1) promoter in multidrug-resistant cells [37]. 
Therefore, the association of histone acetylation levels 
with CRC resistance is of particular importance if the level 
of acetylation predicts combinatorial therapy outcomes. 
The level of histone acetylation, however appears to be 
independent of the deacetylating role of HDAC2 and 
possibly HDAC2 expression represses transcription 
factors activation which controls cancer cell death and 
promotes drug resistance.
It is highly likely that the overall response to 
conventional treatment may be less robust in patients 
that strongly express HDAC2 in their cancer cells. 
Hence, HDAC2 expression in a given tumour might 
be of prognostic value and also predict the response to 
combinatorial (HDACis/drug) therapy. Identification of 
HDAC2 expression as a sensitive “epigenetic biomarker” 
associated with HDACis/DNA damaging agent’s 
resistance may also lead to a new molecular target for 
CRC therapy and could help to improve treatment of the 
disease and provide a more robust mechanistic rationale 
for the use of HDACis. Further work could present an 
opportunity to maximise treatment efficacy by pharmaco-
epigenetic selection of CRC patients treated with HDAC 
inhibitors combined with DNA-damaging therapies. 
Translational protocols for future clinical trials could 
include HDACis as adjuvant therapeutic agents with 
conventional CRC drugs.
MATERIALS AND METHODS
Cell culture
CRC cell lines: HCT116 P53+/+, HCT116 P53-
/-, SW480, and HT-29 were maintained at 37 °C in 
Dulbecco’s modified Eagle’s medium (Sigma-Aldrich, St. 
Louis, MO, USA) supplemented with 10% fetal bovine 
serum (FBS; Sigma) and penicillin/streptomycin in 5% 
CO2.
Immunoblotting
Total proteins were extracted from pelleted cells with 
TGN lysis buffer 50 mMTris-. HCl pH 7.5, 200 mMNaCl, 
50 mM sodium β-glycerophosphate, 50 mM Sodium) and 
subjected to SDS gel electrophoresis. Primary antibodies 
were used according to the manufacturers’ protocols.
Extraction of acid-soluble nuclear proteins  
and WB
To detect single acetylated lysine residue on 
histone H4 and H3 tails, the acid-soluble nuclear proteins 
were extracted as follow: cells were trypsinased and spun 
down, washed with phosphate-buffered saline (PBS) and 
were resuspended in the histone lysis buffer containing 
10 mM Tris (pH 6.5), 50 mM sodium bisulfate, 10 
mM MgCl2, 8.6% sucrose, 1% Triton X-100 and 0.2 
M sulfuric acid completed with protease inhibitors 
(Sigma). Cells lysates were kept on ice for 1 hour before 
being cleared by centrifugation at 11,000 g for 30 min 
at 4°C. The supernatant was precipitated with acetone 
overnight and then centrifuged at 11,000 g for 1 h at 
4°C. Pellets were dried out at room temperature (RT). 
Acid-extracted histones were obtained by centrifugation 
at 11 000 g for 1 h at 4°, and the concentrations of 
the histones were measured by the Bradford method 
(BioRad) according to the manufacturer’s instructions. 
Histone proteins were resuspended in Laemmli buffer 
boiled and separated by SDS–polyacrylamide gel 
electrophoresis (15% gel), Histone proteins were 
transferred on to nitrocellulose membrane (Amersham, 
UK). Membranes were blocked for 2 h with 5% non-fat 
milk in PBS at RT and subsequently probed overnight 
with primary antibodies raised against histone H3 and 
H4 or against acetylated histone lysine H3K9, H4K12 
and H4K16. The membranes were washed three times 
in PBS-0.1% Tween and then incubated for 1h with 
secondary antibodies (HRP-conjugated goat anti-mouse 
or HRP-conjugated goat anti-rabbit. After three washes 
1X PBS with 0.1% Tween 20, bands were detected by 
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enhanced chemiluminescence (ECL Plus) following the 
manufacturer’s instructions (Amersham, UK).
Reagents and antibodies
Doxorubicin (Dox), 2-propylpentanoic acid (VPA) 
and sodium butyrate, oxaliplatin (Oxa), 5-fluorouracil 
(5-FU) were purchased from Sigma-Aldrich (United 
Kingdom). SAHA (vorinostat) was obtained from 
Zolinza (Merck, Whitehouse Station, NJ, USA). anti-
PUMA was purchased from eBioscience (UK), anti-
MDM2 was from Calbiochem, UK, anti-HDAC1, 2, 
anti-phosphorylated or acetylated P53 and anti-PARP 
were obtained from Cell Signaling Technology, UK). 
anti-P53 (Do1) was from GeneTex Inc., USA and anti-
Survivin was from Novus Biologicals, USA, and anti-
β-actin (Sigma–Aldrich). Anti-histone H3 and anti-H4 
(Abcam, Cambridge, UK) or acetylated histone lysine 
H3K9, H4K12 and H4K16 (Upstate Biotechnology, 
Billerica, MA, USA). Binding of primary antibodies 
was detected with a horseradish-peroxidase-conjugated 
goat anti-mouse (Pierce, Rockford, IL, USA). After 
repeated washing in phosphate-buffered saline, bands 
were visualized by enhanced chemiluminescence 
(ECL Plus) following the manufacturer’s instructions 
(Amersham).
Preparation of liposomes
Liposomes for in vivo therapeutic application were 
prepared in organic solvent of N1-cholesteryloxycarbonyl-
3,7-diazanonane-1,9-diamine (CDAN), 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC), cholesterol and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
methoxy(polyethylene glycol)-2000 (DSPE-PEG2000) 
using a spontaneous vesicle formation procedure (19). 
The solvent was then removed in vacuo to ensure 
production of an even lipid. The film was re-hydrated 
and remotely loaded with either 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (4 mM, NaCl 
135 mM, pH 6.5) or with Doxorubicin and SAHA. The 
total lipid concentration in the suspension was 2.88 mg/
mL. The concentration of doxorubicin and SAHA was 
selected to approximate a 20g/ mouse receiving liposomal 
doxorubicin at a dosage of 10 mg/kg and a liposomal 
dosage of SAHA to be 50 mg/kg. The thin- film of 
nanoparticle liposome was obtained by hydration and by 
sonication method for 1hour at 30°C, in order to form the 
required uniform PEGylated liposome, and buffered to 
a pH of 7.0. The liposomal solution was dialyzed for 18 
hours using the Float-A-Lyzer G2 device (Fisher scientific, 
UK) to remove any un-encapsulated materials (19). The 
particles had a component molar ratio of 32/24/8/30 
(CDAN/DOPC/DSPE-PEG PEG2000/cholesterol). 
Particle size and zeta potential were determined using 
a Malvern Zetasizer (Malvern, UK). The size of the 
vesicles was typically 100 nm.
Mitotic cell death
The analysis of cells with mitotic catastrophe was 
based on the quantification of the cells expressing phospho 
H3 (Ser10) with MTC nuclear morphology in mitosis. 
Using immunoblotting (antiphospho-Histone H3 (Ser10)) 
and confocal immunofluorescence analyzes.
MNase sensitivity assay
Cells were lysed in NP-40 lysis buffer (ce-cold NP-
40 lysis buffer (10 mM Tris [pH 7.4], 10 mM NaCl, 3 
mM MgCl2, 0.5% NP-40, 0.15 mM spermine, 0.5 mM 
spermidine) and incubated on ice for 5 minutes.). Nuclei 
were resuspended in Micrococal nuclease (MNase) 
digestion buffer(10 mM Tris-HCl pH 8.0, 1 mM CaCl2). 
A total of 0.06 units of MNase (Sigma-Aldrich, UK) 
was added to each sample and incubated at 15-20°C for 
5 minutes. The reaction was stopped by the addition of 
MNase digestion buffer, MNase stop buffer ((0.5 ml) - 
5% SDS; 250 mM EDTA), proteinase K and 20% SDS 
followed by overnight incubation. DNA was extracted 
by standard phenol/chloroform extraction and ethanol 
precipitation.
Generation of stable cell lines
Stable cell lines were generated after transfection of 
p53-null HCT 116 P53-/- or HT-29 cells with wild type 
P53 plasmid (Origene, UK) or mutant p53 expression 
plasmids generated by using the QuikChange II site-
directed mutagenesis kit (Stratagene) according to the 
manufacturer. The mutated plasmid were sequenced and 
verified by using NCB Blast: Nucleotide Sequence. After 
transfection, the cells that incorporate the plasmids were 
selected by grown them in medium containing 2.5 μg/ml 
of puromycin for 2 weeks. The resulting colonies were 
then pooled and used for further assays than used for 
experiments.
Flow cytometry
Cells were trypsinised, washed, and re-suspended 
in PBS 1Xand distributed in flow cytometry tubes. Cells 
viability was assessed by staining with Propidium iodide 
(PI). Cells were then analyzed using FACSCaliburTM(BD 
Biosciences) machine with the cellQuest program.
Xenograft in vivo models and bioluminescence 
imaging
Experiments were carried out in compliance with 
Animals (Scientific Procedure) Act 1986 under the project 
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licence 70/6656. Stable luciferase HCT116 P53+/+ and 
HCT116 P53-/- clone cell lines were harvested at ~80% 
confluent, re-suspended in serum-free DMEM and 
transplanted intraperitoneally in male Balb-c nude/nude 
mice using a 25 gauge needle. After tumour growth the 
mice (~14 days after inoculation) were randomly assigned 
to either the control (n=4) or test conditions (n=4). The 
size of the tumour in response to the combined treatment 
was measured before treatment and every three days using 
callipers. The volume estimated was measured assuming 
an ellipsoid shape using the following equation:
Volume= length x width x depth x π/6. Animals 
were sacrificed and the tumours were carefully excised 
to minimize any surrounding normal tissue. Tumors were 
weighed, portioned and placed in phosphate-buffered 
in formalin for (Sigma-Aldrich, UK) for histological 
evaluation. Luciferase activity in xenografts mice was 
visualized by luminescence, using the Xenogen IVIS 2000 
small-animal In Vivo Imaging System (Xenogen Corp., 
Alameda, CA).
Mice were treated with a dose of 40 mmol/day of 
Dox/SAHA (200 μL i.p.) combination liposome or 40 
mmol/day of HEPES liposome (test) [19] (. Mice were 
euthanized when severe as cites was observed.
Human liver samples
Human sample were obtained from the archived 
material of the Department of Histopathology, 
Hammersmith Hospital, London, U K, where all the ethics 
are approved.
Imunofluoresence
Assays were performed as previously described 
by us (2). Briefly, Paraformaldehyde- HT-29 fixed cells 
were incubated with primary antibody (anti-HDAC2 or 
anti-phosphorylated- H3) and secondary antibody (594 
conjugated polyclonal goat anti-mouse IgG antibody). 
Cell nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI; 1 μg/ml). Samples were mounted 
with Vectashield (Vector Laboratories, Burlingame, CA, 
USA) and analyzed with Zeiss 510 META confocal laser 
scanning microscopy (Zeiss, Jena, Germany).
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